ENSTILAR

This brand name is authorized in United States. It is also authorized in Australia, Austria, Canada, Croatia, Cyprus, Estonia, Finland, France, Hong Kong SAR China, Ireland, Israel, Lithuania, Malta, Netherlands, New Zealand, Poland, Spain, UK.

Active ingredients

The drug ENSTILAR contains a combination of these active pharmaceutical ingredients (APIs):

1	Calcipotriol UNII S7499TYY6G - CALCIPOTRIENE MONOHYDRATE
	Calcipotriol is a derivative of vitamin D for topical use on psoriasis. It probably works by suppressing keratinization. Advantage of substance or absence of odor and non-coloring of clothing.
	Read more about Calcipotriol
2	Betamethasone UNII 826Y60901U - BETAMETHASONE DIPROPIONATE
	Betamethasone is a glucocorticoid which is about eight to ten times as active as prednisolone on a weight-for-weight basis. Betamethasone has anti-inflammatory, antipruritic, and vasoconstrictive properties.
	Read more about Betamethasone

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
ENSTILAR Foam	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
D05AX52	Calcipotriol, combinations	D Dermatologicals → D05 Antipsoriatics → D05A Antipsoriatics for topical use → D05AX Other antipsoriatics for topical use
Discover more medicines within D05AX52

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	11091R
CA	Health Products and Food Branch	02457393
EE	Ravimiamet	1680050, 1680061
ES	Centro de información online de medicamentos de la AEMPS	80896
FI	Lääkealan turvallisuus- ja kehittämiskeskus	561259, 579406
FR	Base de données publique des médicaments	67347855
GB	Medicines & Healthcare Products Regulatory Agency	326154, 351733, 380788, 381332, 387248
HK	Department of Health Drug Office	66143
HR	Agencija za lijekove i medicinske proizvode	HR-H-453098022
IE	Health Products Regulatory Authority	43072, 43073
IL	מִשְׂרַד הַבְּרִיאוּת	8625
LT	Valstybinė vaistų kontrolės tarnyba	1075861, 1080064
MT	Medicines Authority	MA024/01101
NL	Z-Index G-Standaard, PRK	133329
NZ	Medicines and Medical Devices Safety Authority	18324
PL	Rejestru Produktów Leczniczych	100339770
US	FDA, National Drug Code	50222-302